CHINA SXT PHARMACEUTICALS IN (SXTC)
VGG2161P1403 - Common Stock
| MRQ (2023-9-30) | 2023 (2023-3-31) | 2022 (2022-3-31) | 2021 (2021-3-31) | 2020 (2020-3-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 11.47M | 17.37M | 15.52M | 13.33M | 7.29M | |||
| Receivables | 1.28M | 1.34M | 5.53M | 6.66M | 9.70M | |||
| Inventories | 493.21K | 530.00K | 1.02M | 860.00K | 890.00K | |||
| Other Current Assets | 252.18K | 280.00K | 380.00K | 2.38M | 1.75M | |||
| Total Current Assets | 13.50M | 19.52M | 22.45M | 23.23M | 19.64M | |||
| Non-Current Assets | ||||||||
| PPE Net | 1.07M | 1.27M | 1.59M | 1.79M | 1.90M | |||
| Intangibles | 22.51K | 30.00K | 40.00K | 50.00K | 50.00K | |||
| Other Non-Current Assets | 0.00 | 8.74M | 9.46M | 9.48M | 110.00K | |||
| Total Non-Current Assets | 1.09M | 10.03M | 11.10M | 11.32M | 2.06M | |||
| TOTAL ASSETS | 14.59M | 29.55M | 33.55M | 34.55M | 21.70M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 267.27K | 170.00K | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 2.52M | 3.17M | 2.05M | 40.00K | 6.69M | |||
| Accrued Expenses | 1.31M | 1.12M | 970.00K | 1.17M | 640.00K | |||
| Accounts Payable | 1.32M | 1.38M | 1.48M | 1.46M | 1.94M | |||
| Other Current Liabilities | 3.79M | 8.67M | 12.62M | 15.92M | 3.00M | |||
| Total Current Liabilities | 9.20M | 14.50M | 17.12M | 18.58M | 12.26M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 106.58K | 120.00K | 0.00 | 10.00K | 40.00K | |||
| Other Non-Current Liabilities | 204.94K | 250.00K | N/A | N/A | N/A | |||
| Total Non-Current Liabilities | 311.52K | 360.00K | 0.00 | 10.00K | 40.00K | |||
| TOTAL LIABILITIES | 9.51M | 14.86M | 17.12M | 18.59M | 12.30M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -31.31M | -21.61M | -15.69M | -9.95M | -7.20M | |||
| Additional Paid In Capital | 35.95M | 35.59M | 30.99M | 25.32M | 17.16M | |||
| Common Shares | 1.45M | 910.00K | 160.00K | 60.00K | 30.00K | |||
| Other Shareholders' Equity | -1.02M | -200.00K | 960.00K | 530.00K | -590.00K | |||
| Shares Outstanding | 727.85K | 460.00K | 80.00K | 30.00K | 20.00K | |||
| Tangible Book Value per Share | 6.94 | 31.87 | 204.75 | 530.33 | 467.50 | |||
| Total Shareholders' Equity | 5.08M | 14.69M | 16.42M | 15.96M | 9.40M | |||
| TOTAL LIABILITIES AND EQUITY | 14.59M | 29.55M | 33.55M | 34.55M | 21.70M | |||
| Statistics | ||||||||
| Debt/Equity | 0.07 | 0.02 | N/A | 0.00 | 0.00 | |||
| Current Ratio | 1.47 | 1.35 | 1.31 | 1.25 | 1.60 | |||
| Return On Assets (ROA) | -96.90% | -20.07% | -17.11% | -7.96% | -47.42% | |||
| Return On Equity (ROE) | -278.47% | -40.37% | -34.96% | -17.23% | -109.47% | |||
| Return On Invested Capital (ROIC) | N/A | N/A | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash (ROICexc) | N/A | N/A | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | N/A | N/A | N/A | N/A | N/A | |||
All data in USD